市場調査レポート

商品コード

1566177

免疫学の市場規模、シェア、成長分析、薬剤クラス別、疾患適応症別、流通チャネル別、地域別 - 産業予測、2024年～2031年

Immunology Market Size, Share, Growth Analysis, By Drug Class, By Disease Indication, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日: 2024年10月01日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 779,047円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 911,338円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,043,629円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.99円

全表示
概要
目次

概要

サンプル依頼リストに入れる

免疫学の世界市場規模は2022年に958億米ドルと評価され、2023年の1,074億9,000万米ドルから2031年には2,699億6,000万米ドルに成長し、予測期間中（2024-2031年）のCAGRは12.20%で推移する見通しです。

世界の免疫学市場は、自己免疫疾患、がん、アレルギー、感染症など、さまざまな免疫関連疾患に対する革新的な治療法や診断法の開拓に注力する、ヘルスケアおよび製薬分野の中でも急速に変化している分野です。これらの疾患の有病率の上昇に牽引され、効果的な免疫学的治療に対する需要が急増しています。最近のバイオテクノロジーと分子生物学の進歩は、標的免疫療法の創出を促進し、市場の成長を後押ししています。しかし、治療費の高騰、厳しい規制環境、複雑な保険償還の枠組みなど、治療法の普及を妨げる大きな課題も抱えています。さらに、新興国では最先端の治療に対する認識やアクセスが限られているため、市場の拡大が制限される可能性があります。主なハードルとしては、疾患メカニズムのより深い理解、より正確な患者層別化のためのバイオマーカーの同定、個別化免疫療法の開発などが挙げられるが、これらはすべて免疫系の複雑な性質と他の身体プロセスとの相互作用によって複雑に絡み合っています。とはいえ、ゲノムおよびプロテオミクス技術の進歩や、免疫制御に関する習熟の進展によって、将来有望な機会が待ち受けています。プレシジョン・メディシンの台頭や、免疫学的戦略と他の治療法との統合の可能性により、専門的な治療が可能になる見込みが高まっています。全体として、世界の免疫学市場は様々な課題に直面しているが、これらの課題に対処し、イノベーションの機会を活用することで、免疫関連疾患の治療における変革的進歩につながる可能性があります。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

AbbVie, Inc.（U.S.）
Janssen Global Services, LLC（U.S.）
Eli Lilly and Company（U.S.）
Novartis AG（Switzerland）
Pfizer Inc.（U.S.）
Bristol-Myers Squibb Company（U.S.）
Merck Sharp & Dohme Corp.（U.S.）
F. Hoffmann-La Roche Ltd.（Switzerland）
Amgen Inc.（U.S.）
Astellas Pharma Inc.（Japan）
UCB SA（Belgium）
Sanofi（France）
Gilead Sciences, Inc.（U.S.）
Regeneron Pharmaceuticals, Inc.（U.S.）
Teva Pharmaceutical Industries Ltd.（Israel）
Takeda Pharmaceutical Company Limited（Japan）
Horizon Therapeutics plc（Ireland）
Aimmune Therapeutics, Inc.（U.S.）
Celgene Corporation（U.S.）
Incyte Corporation（U.S.）
Boehringer Ingelheim GmbH（Germany）
Abbott Laboratories（U.S.）

Product Code: SQMIG35H2245

Global Immunology Market size was valued at USD 95.8 billion in 2022 and is poised to grow from USD 107.49 billion in 2023 to USD 269.96 billion by 2031, growing at a CAGR of 12.20% during the forecast period (2024-2031).

The global immunology market is a rapidly changing segment within the healthcare and pharmaceutical sectors, focused on developing innovative therapies and diagnostics for various immune-related disorders, such as autoimmune diseases, cancer, allergies, and infectious diseases. Driven by the rising prevalence of these conditions, there is an urgent demand for effective immunological treatments. Recent advancements in biotechnology and molecular biology have facilitated the creation of targeted immunotherapies, propelling market growth. However, the sector also faces significant challenges, including high treatment costs, stringent regulatory environments, and complex reimbursement frameworks that impede the widespread adoption of therapies. Furthermore, limited awareness and access to cutting-edge treatments in developing regions can restrict market expansion. Key hurdles include the need for deeper understanding of disease mechanisms, the identification of biomarkers for more accurate patient stratification, and the development of personalized immunotherapies, all compounded by the intricate nature of the immune system and its interactions with other bodily processes. Nevertheless, promising opportunities lie ahead, driven by advancements in genomic and proteomic technologies and a growing mastery of immune regulation. The rise of precision medicine and the potential integration of immunological strategies with other treatment modalities enhance prospects for specialized interventions. Overall, while the global immunology market confronts various challenges, addressing these issues and leveraging opportunities for innovation can lead to transformative advancements in the treatment of immune-related disorders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Immunology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Immunology Market Segmental Analysis

Global Immunology Market is segmented by Drug Class, Disease Indication, Distribution Channel, and region. Based on Drug Class, the market is segmented into Monoclonal Antibody, Immunosuppressants, Fusion Proteins, Others. Based on Disease Indication, the market is segmented into Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Immunology Market

The rapid advancements in biotechnology serve as a crucial market driver for the Global Immunology market, revolutionizing treatment options for immune-related disorders. With the introduction of novel biologics and targeted therapies, such as the FDA-approved bimekizumab for psoriasis and psoriatic arthritis, the therapeutic landscape is witnessing transformative shifts. These innovations not only offer superior efficacy compared to traditional treatments but also enhance patient outcomes significantly. As the demand for effective and tailored therapies rises, the integration of cutting-edge biotechnological developments will continue to propel growth in the immunology sector, fostering further research and investment in this dynamic field.

Restraints in the Global Immunology Market

The global immunology market faces considerable restraints due to the high costs associated with immunological therapies. The intricate processes involved in the development and manufacturing of biologics and targeted therapies contribute to elevated production costs, which are subsequently passed on to patients and healthcare systems. This financial burden restricts access to these innovative treatment options, particularly in developing regions where healthcare budgets are limited. Moreover, the persistent challenge of affordability stifles broader adoption of immunological interventions, hindering advancements in patient care and impeding market growth. As a result, addressing these economic barriers is crucial for the future expansion of the immunology sector.

Market Trends of the Global Immunology Market

The global immunology market is experiencing a significant shift towards personalized medicine, driven by advancements in biomarker development. Companies and researchers are increasingly investing in identifying specific biomarkers that can stratify patient populations, allowing for tailored immunotherapy approaches. This trend not only enhances treatment efficacy but also minimizes adverse reactions by ensuring that patients receive therapies tailored to their unique biological profiles. The growing demand for precision medicine, combined with technological innovations and regulatory support, positions personalized immunology therapies as a pivotal area of growth in the market, promising enhanced patient outcomes and a more targeted approach to immunological diseases.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Immunology Market by Drug Class

Market Overview
Monoclonal Antibody
Immunosuppressants
Fusion Proteins
Others

Immunology Market by Disease Indication

Market Overview
Rheumatoid Arthritis
Psoriatic Arthritis
Plaque Psoriasis
Ankylosing Spondylitis
Inflammatory Bowel Disease
Prophylaxis of Organ Rejection
Others

Immunology Market by Distribution Channel

Market Overview
Offline Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Online Channel

Immunology Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

AbbVie, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Janssen Global Services, LLC (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck Sharp & Dohme Corp. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB SA (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Horizon Therapeutics plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aimmune Therapeutics, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

免疫学の市場規模、シェア、成長分析、薬剤クラス別、疾患適応症別、流通チャネル別、地域別 - 産業予測、2024年～2031年

Immunology Market Size, Share, Growth Analysis, By Drug Class, By Disease Indication, By Distribution Channel, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

免疫学市場：薬剤クラス別

免疫学市場：疾患適応症別

免疫学市場：流通チャネル別

免疫学市場規模：地域別